NR565 ADVANCED PHARMACOLOGY
FUNDAMENTALS WEEK 8 FINAL
EXAM 2026/2027: 100 QUESTIONS
SECTION 1: Prescribing Principles & Safety (15 Questions)
Q1: A 28-year-old woman with epilepsy stabilized on lamotrigine requests prepregnancy
counseling. She is planning to conceive in 3 months. What is the MOST
appropriatepharmacological advice?
A. Continue current lamotrigine dose throughout pregnancy.
B.Switch to levetiracetam prior to conception due to better pregnancy safety data.C.
Discontinue all antiseizure drugs during first trimester.
D. Add folic acid 0.4 mg daily when she becomes pregnant.
Correct Answer: B Rationale: Guideline & Safety: Per AAN and ACOG guidelines,
prepregnancy planning is critical for women with epilepsy.
Drug-Specific Risk: Lamotrigine has increased clearance during pregnancy, requiring
frequent level monitoring and dose adjustments. Levetiracetam has more consistent
pharmacokinetics and favorable pregnancy registry data.
Folic Acid: Should be started at higher dose (4 mg daily) at least 1 month before conception
in women on antiseizure drugs to prevent neural tube defects (D is incorrect dose and timing).
Monitoring: Drug levels should be monitored each trimester and postpartum.
Reference: Epilepsy Foundation & AAN Practice Guidelines.
Q2: Which medication carries a Black Box Warningfor increased risk of suicidal thoughts
and behaviors in young adults?
A. Metoprolol
B. Lisinopril
C.Sertraline D. Metformin
Correct Answer: C Rationale: FDA Requirement: All SSRI antidepressants (including
sertraline) carry a Black Box Warning for increased risk of suicidal thinking and behavior in
children, adolescents, and young adults (ages 18-24), especially during initial treatment or
dose changes.
NP Monitoring Responsibility: Requires close monitoring for worsening depression,
agitation, or unusual behavior changes, particularly during first few months of therapy.
Patient Education: Must discuss this risk with patient/family.
Comparison: The other medications do not have this specific warning.
Q3:A patient is prescribed a drug with a narrow therapeutic index. Which statement best
describes the NP's responsibility regarding this medication?
A. Monitoring is only necessary if the patient reports side effects.
,B.Serum drug levels must be monitored regularly to ensure efficacy and prevent
toxicity.C. These drugs are generally safer because they are more potent.
D. Dose adjustments should only be made based on patient weight.
Correct Answer: B Rationale: Pharmacokinetics: Drugs with a narrow therapeutic index
(NTI) have a small window between the effective dose and the toxic dose (e.g., digoxin,
lithium, phenytoin). NP Responsibility: Requires precise dosing and therapeutic drug
monitoring (TDM). Safety: Small changes in serum concentration can lead to therapeutic
failure or severe toxicity. Monitoring: Baseline and periodic serum levels are mandatory.
Q4: When prescribing a medication that is a known CYP3A4 inducer, what is the expected
effect on a co-administered drug that is a CYP3A4 substrate?
A. Increased serum levels of the substrate drug.
B.Decreased serum levels of the substrate drug, potentially leading to therapeutic
failure.C. No change in the metabolism of the substrate drug.
D. Increased risk of toxicity of the substrate drug.
Correct Answer: B Rationale: Metabolism: CYP450 inducers (e.g., rifampin,
carbamazepine, St. John's Wort) increase the production of metabolic enzymes. Effect: This
leads to faster metabolism of substrate drugs, resulting in lower serum concentrations and
reduced efficacy. NP Action: May need to increase the dose of the substrate drug or choose
an alternative. Contrast: Inhibitors (like grapefruit juice) would increase levels (A and D).
Q5:A 45-year-old patient with chronic kidney disease (CKD) Stage 4 is being prescribed a
new medication that is primarily renally excreted. How should the NP adjust the initial
dosing?
A. Start with the standard adult dose.
B.Start with a lower dose or increase the dosing interval based on estimated GFR.C.
Avoid all renally excreted drugs in CKD.
D. Increase the dose to compensate for poor kidney function.
Correct Answer: B Rationale: Excretion: In CKD, the kidneys' ability to clear drugs is
reduced, leading to drug accumulation and toxicity. Adjustment: Dosing must be tailored
to the patient's renal function (usually CrCl or eGFR). Strategies: Either reduce the
individual dose or prolong the interval between doses. Safety: Failure to adjust can lead to
severe adverse events.
Q6: Which of the following is a requirement for a medication to be classified as a Schedule
IIcontrolled substance?
A. No accepted medical use in the United States.
B.High potential for abuse which may lead to severe psychological or physical
dependence.C. Low potential for abuse relative to Schedule III.
D. Can be refilled up to five times in six months.
Correct Answer: B Rationale: DEA Classification: Schedule II drugs (e.g., oxycodone,
fentanyl, methylphenidate) have a high potential for abuse but have currently accepted
medical uses. Restrictions: No refills are allowed; a new prescription is required each time.
, Comparison: Schedule I (A) has no accepted medical use. Schedule III-V have lower abuse
potential.
Q7:A patient reports an "allergy" to penicillin, describing a rash that appeared 3 days after
starting the medication. What is the most appropriate next step for the NP?
A. Document a life-threatening allergy and avoid all beta-lactams.
B.Clarify the type of reaction to distinguish between a Type I hypersensitivity and a
non-allergic rash.C. Administer a test dose of amoxicillin in the clinic.
D. Prescribe a cephalosporin immediately as there is no cross-reactivity.
Correct Answer: B Rationale: Clinical Reasoning: Many patients report penicillin
allergies that are actually non-allergic side effects or non-IgE mediated rashes. Type I vs. IV:
A rash appearing after 3 days is likely a Type IV (delayed) reaction, not a life-threatening
Type I (anaphylaxis). NP Action: Detailed history is essential to determine if cephalosporins
(which have ~1-4% cross-reactivity) can be safely used.
Q8: What is the primary purpose of the FDA's MedWatchprogram?
A. To regulate the price of prescription drugs.
B.To provide a voluntary reporting system for adverse events and product quality
problems.C. To fast-track the approval of new vaccines.
D. To provide insurance coverage for experimental treatments.
Correct Answer: B Rationale: Post-Marketing Surveillance: MedWatch allows healthcare
professionals and consumers to report serious adverse events, potential medical errors, and
product defects. Safety: This data helps the FDA identify safety signals that were not
apparent during clinical trials. NP Role: NPs should actively participate in reporting
unexpected drug reactions.
Q9:A patient is prescribed a "prodrug." What must occur for this medication to become
therapeutically active?
A. It must be taken on an empty stomach.
B.It must undergo metabolic conversion, usually in the liver.C. It must be administered
intravenously to bypass the liver.
D. It must be bound to plasma proteins like albumin.
Correct Answer: B Rationale: Pharmacokinetics: A prodrug (e.g., codeine, enalapril,
clopidogrel) is pharmacologically inactive when administered. Activation: It requires
biotransformation (often by CYP450 enzymes) into its active metabolite. Clinical
Significance: Patients with genetic polymorphisms (e.g., poor metabolizers of CYP2D6) may
not achieve therapeutic levels of the active drug.
Q10: Which pharmacokinetic process is most affected by a patient's serum albuminlevels?
A. Absorption
B.DistributionC. Metabolism
D. Excretion
FUNDAMENTALS WEEK 8 FINAL
EXAM 2026/2027: 100 QUESTIONS
SECTION 1: Prescribing Principles & Safety (15 Questions)
Q1: A 28-year-old woman with epilepsy stabilized on lamotrigine requests prepregnancy
counseling. She is planning to conceive in 3 months. What is the MOST
appropriatepharmacological advice?
A. Continue current lamotrigine dose throughout pregnancy.
B.Switch to levetiracetam prior to conception due to better pregnancy safety data.C.
Discontinue all antiseizure drugs during first trimester.
D. Add folic acid 0.4 mg daily when she becomes pregnant.
Correct Answer: B Rationale: Guideline & Safety: Per AAN and ACOG guidelines,
prepregnancy planning is critical for women with epilepsy.
Drug-Specific Risk: Lamotrigine has increased clearance during pregnancy, requiring
frequent level monitoring and dose adjustments. Levetiracetam has more consistent
pharmacokinetics and favorable pregnancy registry data.
Folic Acid: Should be started at higher dose (4 mg daily) at least 1 month before conception
in women on antiseizure drugs to prevent neural tube defects (D is incorrect dose and timing).
Monitoring: Drug levels should be monitored each trimester and postpartum.
Reference: Epilepsy Foundation & AAN Practice Guidelines.
Q2: Which medication carries a Black Box Warningfor increased risk of suicidal thoughts
and behaviors in young adults?
A. Metoprolol
B. Lisinopril
C.Sertraline D. Metformin
Correct Answer: C Rationale: FDA Requirement: All SSRI antidepressants (including
sertraline) carry a Black Box Warning for increased risk of suicidal thinking and behavior in
children, adolescents, and young adults (ages 18-24), especially during initial treatment or
dose changes.
NP Monitoring Responsibility: Requires close monitoring for worsening depression,
agitation, or unusual behavior changes, particularly during first few months of therapy.
Patient Education: Must discuss this risk with patient/family.
Comparison: The other medications do not have this specific warning.
Q3:A patient is prescribed a drug with a narrow therapeutic index. Which statement best
describes the NP's responsibility regarding this medication?
A. Monitoring is only necessary if the patient reports side effects.
,B.Serum drug levels must be monitored regularly to ensure efficacy and prevent
toxicity.C. These drugs are generally safer because they are more potent.
D. Dose adjustments should only be made based on patient weight.
Correct Answer: B Rationale: Pharmacokinetics: Drugs with a narrow therapeutic index
(NTI) have a small window between the effective dose and the toxic dose (e.g., digoxin,
lithium, phenytoin). NP Responsibility: Requires precise dosing and therapeutic drug
monitoring (TDM). Safety: Small changes in serum concentration can lead to therapeutic
failure or severe toxicity. Monitoring: Baseline and periodic serum levels are mandatory.
Q4: When prescribing a medication that is a known CYP3A4 inducer, what is the expected
effect on a co-administered drug that is a CYP3A4 substrate?
A. Increased serum levels of the substrate drug.
B.Decreased serum levels of the substrate drug, potentially leading to therapeutic
failure.C. No change in the metabolism of the substrate drug.
D. Increased risk of toxicity of the substrate drug.
Correct Answer: B Rationale: Metabolism: CYP450 inducers (e.g., rifampin,
carbamazepine, St. John's Wort) increase the production of metabolic enzymes. Effect: This
leads to faster metabolism of substrate drugs, resulting in lower serum concentrations and
reduced efficacy. NP Action: May need to increase the dose of the substrate drug or choose
an alternative. Contrast: Inhibitors (like grapefruit juice) would increase levels (A and D).
Q5:A 45-year-old patient with chronic kidney disease (CKD) Stage 4 is being prescribed a
new medication that is primarily renally excreted. How should the NP adjust the initial
dosing?
A. Start with the standard adult dose.
B.Start with a lower dose or increase the dosing interval based on estimated GFR.C.
Avoid all renally excreted drugs in CKD.
D. Increase the dose to compensate for poor kidney function.
Correct Answer: B Rationale: Excretion: In CKD, the kidneys' ability to clear drugs is
reduced, leading to drug accumulation and toxicity. Adjustment: Dosing must be tailored
to the patient's renal function (usually CrCl or eGFR). Strategies: Either reduce the
individual dose or prolong the interval between doses. Safety: Failure to adjust can lead to
severe adverse events.
Q6: Which of the following is a requirement for a medication to be classified as a Schedule
IIcontrolled substance?
A. No accepted medical use in the United States.
B.High potential for abuse which may lead to severe psychological or physical
dependence.C. Low potential for abuse relative to Schedule III.
D. Can be refilled up to five times in six months.
Correct Answer: B Rationale: DEA Classification: Schedule II drugs (e.g., oxycodone,
fentanyl, methylphenidate) have a high potential for abuse but have currently accepted
medical uses. Restrictions: No refills are allowed; a new prescription is required each time.
, Comparison: Schedule I (A) has no accepted medical use. Schedule III-V have lower abuse
potential.
Q7:A patient reports an "allergy" to penicillin, describing a rash that appeared 3 days after
starting the medication. What is the most appropriate next step for the NP?
A. Document a life-threatening allergy and avoid all beta-lactams.
B.Clarify the type of reaction to distinguish between a Type I hypersensitivity and a
non-allergic rash.C. Administer a test dose of amoxicillin in the clinic.
D. Prescribe a cephalosporin immediately as there is no cross-reactivity.
Correct Answer: B Rationale: Clinical Reasoning: Many patients report penicillin
allergies that are actually non-allergic side effects or non-IgE mediated rashes. Type I vs. IV:
A rash appearing after 3 days is likely a Type IV (delayed) reaction, not a life-threatening
Type I (anaphylaxis). NP Action: Detailed history is essential to determine if cephalosporins
(which have ~1-4% cross-reactivity) can be safely used.
Q8: What is the primary purpose of the FDA's MedWatchprogram?
A. To regulate the price of prescription drugs.
B.To provide a voluntary reporting system for adverse events and product quality
problems.C. To fast-track the approval of new vaccines.
D. To provide insurance coverage for experimental treatments.
Correct Answer: B Rationale: Post-Marketing Surveillance: MedWatch allows healthcare
professionals and consumers to report serious adverse events, potential medical errors, and
product defects. Safety: This data helps the FDA identify safety signals that were not
apparent during clinical trials. NP Role: NPs should actively participate in reporting
unexpected drug reactions.
Q9:A patient is prescribed a "prodrug." What must occur for this medication to become
therapeutically active?
A. It must be taken on an empty stomach.
B.It must undergo metabolic conversion, usually in the liver.C. It must be administered
intravenously to bypass the liver.
D. It must be bound to plasma proteins like albumin.
Correct Answer: B Rationale: Pharmacokinetics: A prodrug (e.g., codeine, enalapril,
clopidogrel) is pharmacologically inactive when administered. Activation: It requires
biotransformation (often by CYP450 enzymes) into its active metabolite. Clinical
Significance: Patients with genetic polymorphisms (e.g., poor metabolizers of CYP2D6) may
not achieve therapeutic levels of the active drug.
Q10: Which pharmacokinetic process is most affected by a patient's serum albuminlevels?
A. Absorption
B.DistributionC. Metabolism
D. Excretion
